HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account

Clinical Expertise

At The Colorado Blood Cancer Institute he developed an investigator initiated a phase 1 protocol for patients with chemotherapy-refractory AML/MDS using GVHD prophylaxis with posttransplant cyclophosphamide followed by PD-1 inhibition with Nivolumab for consolidation. This protocol now offers a potentially curative treatment option for patients that otherwise would not meet criteria to undergo allogenic stem cell transplantation.

Location

Colorado Blood Cancer Institute: 1721 E 19th Ave Ste. 300, Denver, CO 80218, USA

Get the latest thought leadership on AML delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.

Thanks to our HealthTree Community for AML Sponsors:

Jazz Pharmaceuticals
AbbVie
Amgen
Genentech
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube